Pharmaceutical giant Pfizer has struck a deal to let generic drug manufacturers produce its experimental COVID-19 antiviral pill, in an effort to make treatments more accessible to lower-income countries.
Pfizer's antiviral pill is designed to stop the virus from replicating and trial data reportedly shows it provides a high chance of preventing hospitalization.
But as Crystal Goomansingh explains, the deal only involves about half of the world's population.
For more info, please go to https://globalnews.ca/news/8376742/pfizer-covid-19-pill-patent-wave/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#GlobalNews #COVID-19 #PfizerPill
Pfizer's antiviral pill is designed to stop the virus from replicating and trial data reportedly shows it provides a high chance of preventing hospitalization.
But as Crystal Goomansingh explains, the deal only involves about half of the world's population.
For more info, please go to https://globalnews.ca/news/8376742/pfizer-covid-19-pill-patent-wave/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#GlobalNews #COVID-19 #PfizerPill
- Category
- U.S. & Canada
- Tags
- global news, Pfizer, COVID-19
Sign in or sign up to post comments.
Be the first to comment